NICE reviews number crunching methods as advanced technologi...

NICE is to review how it develops guidance on drugs, focusing on issues such as modifiers used in decision making and dealing with uncertainties in evidence.

Roche under pressure in US as Amgen/Allergan launch US cance...

Amgen and Allergan have launched their cut-price biosimilar competitors to two big-selling cancer drugs from Roche in the US.

FDA clears Bayer’s Gadavist as first contrast agent for card...

Merck gets FDA nod for new antibiotic, but says use with car...

As R&D shrinks, UK trials new payment scheme for antibiotics

NICE restores parity between Alnylam and Akcea on rare disea...